tailieunhanh - Báo cáo y học: " Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A3"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Wertheim cung cấp cho các bạn kiến thức về ngành y đề tài: Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328. | Bosch et al. AIDS Research and Therapy 2010 7 30 http content 7 1 30 AIDS RESEARCH AND THERAPY RESEARCH Open Access Continuing or adding IL-2 in patients treated with antiretroviral therapy ACTG Protocol A5051 a rollover trial of ACTG Protocol A328 D I 1 I D D D I I 2 A I I 3 r I . x- A . 1 I c Z X 4 D I I I r I h 1 r I5 Ronald J Bosch Richard B Pollard Alan Landay Evgenia Aga Lawrence Fox Ronald Mitsuyasu Abstract Background Effective antiretroviral therapy reduces HIV-1 RNA levels improves CD4 T-cell counts and lowers the risk of opportunistic infections and malignancies. Interleukin-2 IL-2 has been shown to increase CD4 T-cell numbers mainly by expanding CD4 cells and by prolonging their half-lives. HIV-infected patients previously enrolled into A328 had been randomized to antiretroviral therapy ART alone or ART followed by IL-2. In A5051 53 patients from A328 who had previously received IL-2 were allowed to continue IL-2 for an additional 80 weeks 27 patients who had received ART alone received IL-2 for 80 weeks. Results The patients previously receiving IL-2 continued to have elevated CD4 levels with extended use of IL-2. The prior ART-alone recipients had increases in CD4 levels to comparable levels as the prior IL-2 recipients median 804 versus 847 cells mm3 at week 72 60 versus 9 had 50 increase in A5051 to week 72 p . Those who had previously received IL-2 required fewer IL-2 cycles to maintain their CD4 T-cell counts compared to those newly initiating IL-2. The treatments were well tolerated with no significant differences in toxicity or discontinuations between those newly versus previously receiving IL-2. There were few clinical events observed. Conclusions Although sustained CD4 T-cell count increases were seen with IL-2 administration as in other studies the absence of clinical benefit in two recent randomized trials has demonstrated no apparent role for IL-2 as a therapy in HIV disease. Trial Registration A5051 .

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN
crossorigin="anonymous">
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.